AR083842A1 - Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a las angiogenesis - Google Patents
Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a las angiogenesisInfo
- Publication number
- AR083842A1 AR083842A1 ARP110104216A ARP110104216A AR083842A1 AR 083842 A1 AR083842 A1 AR 083842A1 AR P110104216 A ARP110104216 A AR P110104216A AR P110104216 A ARP110104216 A AR P110104216A AR 083842 A1 AR083842 A1 AR 083842A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- cycloalkyl
- aryl
- general formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones farmacéuticas que contienen dichos compuestos. Uso de dichos compuestos o de dichas composiciones en la inhibición de la fosfotidilinositol-3-quinasa (PI3K) y en el tratamiento de enfermedades asociadas a la fosfotidilinositol-3-quinasa (PI3K), particularmente en el tratamiento de trastornos hiperproliferativos y/o relacionados con la angiogénesis, solos o en combinación con otros ingredientes activos.Reivindicación 1: Un compuesto de fórmula general (1) en donde: R1 representa -(CH2)n-(CHR4)-(CH2)m-N(R5)(R5’); R2 representa un heteroarilo de estructura de formula (2) opcionalmente sustituido con 1, 2 ó 3 grupos R6, en donde: * representa el punto de unión de dicho heteroarilo con el resto del compuesto de fórmula general (1), X representa N o C-R6, X’ representa O, S, NH, N-R6, N o C-R6, con la condición de que cuando X y X’ son ambos C-R6, luego un C-R6 es C-H; R3 es metilo; R4 es hidroxi; R5 y R5’ son iguales o diferentes y son, en forma independiente entre sí, un átomo de hidrógeno, o un alquilo C1-6, cicloalquil C3-6-alquilo C1-6, o alcoxi C1-6-alquilo C1-6, o R5 y R5’, tomados juntos con el átomo de nitrógeno al cual están unidos, representan un anillo heterocíclico que contiene nitrógeno de entre 3 y 7 miembros que contiene opcionalmente al menos un heteroátomo adicional seleccionado entre oxígeno, nitrógeno o azufre y que puede estar opcionalmente sustituido con 1 o más grupos R6’; las instancias de R6 pueden ser iguales o diferentes y son en forma independiente un átomo de hidrógeno, un átomo de halógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-6, arilo, aril-alquilo C1-6, heteroarilo, heteroaril-alquilo C1-6, anillo heterocíclico de entre 3 y 8 miembros, heterociclilo-alquilo C1-6 de entre 3 y 8 miembros, -alquil C1-6-OR7, -alquil C1-6-SR7, -alquil C1-6-N(R7)(R7’), -alquil C1-6-C(=O)R7, -CN, -C(=O)OR7, -C(=O)N(R7)(R7’), -OR7, -SR7, -N(R7) (R7’), o -NR7C(=O)R7 cada uno de los cuales puede estar opcionalmente sustituido con 1 o más grupos R8; las instancias de R6’ pueden ser iguales o diferentes y son en forma independiente alquilo C1-6, cicloalquil C3-6-alquilo C1-6, o alquil C1-6-OR7; las instancias de R7 y R7’ pueden ser iguales o diferentes y son en forma independiente un átomo de hidrógeno, o un alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-6, cicloalquenilo C3-6, arilo, aril-alquilo C1-6, heteroarilo, anillo heterocíclico de entre 3 y 8 miembros, heterociclil-alquilo C1-6 de entre 3 y 8 miembros, o heteroaril-alquilo C1-6; las instancias de R8 son en forma independiente un átomo de halógeno, o nitro, hidroxi, ciano, formilo, acetilo, amino, alquilo C1-6, alcoxi C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-6, cicloalquenilo C1-6, arilo, aril-alquilo C1-6, heteroarilo, anillo heterocíclico de entre 3 y 8 miembros, heterociclil-alquilo C1-6, o heteroaril-alquilo C1-6; n es el número entero 1 y m es el número entero 1; con la condición de que cuando: dichos R5 y R5’, tomados juntos con el átomo de nitrógeno al cual están unidos, representan el resto de formula (3) en donde * representa el punto de unión con el resto de la estructura de fórmula general (1), entonces dicho R2 heteroarilo de estructura de la formula (2) no es un resto de formula (4) en donde * representa el punto de unión con el resto de la estructura de fórmula general (1); o un estereoisómero, un tautómero, un N-óxido, un hidrato, un solvato o una sal del mismo, en particular una sal fisiológicamente aceptable, o una mezcla de los mismos. Reivindicación 17: Un compuesto de fórmula general (5) en donde R1 y R3 son como se los definió para la fórmula general (1) en cualquiera de las reivindicaciones 1 a 9.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41255610P | 2010-11-11 | 2010-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR083842A1 true AR083842A1 (es) | 2013-03-27 |
Family
ID=44999756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110104216A AR083842A1 (es) | 2010-11-11 | 2011-11-11 | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a las angiogenesis |
Country Status (31)
Country | Link |
---|---|
US (2) | US8895549B2 (es) |
EP (1) | EP2638045B1 (es) |
JP (1) | JP6196156B2 (es) |
KR (1) | KR20140003436A (es) |
CN (1) | CN102906094B (es) |
AP (1) | AP3337A (es) |
AR (1) | AR083842A1 (es) |
AU (1) | AU2011328192B2 (es) |
BR (1) | BR112013011634A2 (es) |
CA (1) | CA2817317C (es) |
CL (1) | CL2013001295A1 (es) |
CO (1) | CO6761350A2 (es) |
CR (1) | CR20130213A (es) |
CU (1) | CU20130069A7 (es) |
DO (1) | DOP2013000105A (es) |
EA (1) | EA024406B1 (es) |
EC (1) | ECSP13012618A (es) |
GT (1) | GT201300121A (es) |
HK (1) | HK1180685A1 (es) |
IL (1) | IL226066A0 (es) |
MA (1) | MA34655B1 (es) |
MX (1) | MX2013005305A (es) |
MY (1) | MY164730A (es) |
NZ (1) | NZ610018A (es) |
PE (1) | PE20140411A1 (es) |
SG (1) | SG190100A1 (es) |
TW (1) | TW201305170A (es) |
UA (1) | UA113280C2 (es) |
UY (1) | UY33719A (es) |
WO (1) | WO2012062748A1 (es) |
ZA (1) | ZA201304244B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2639402T3 (es) * | 2010-11-11 | 2017-10-26 | Bayer Intellectual Property Gmbh | 2,3-dihidroimidazo[1,2-c]quinolinas sustituidas con arilaminoalcohol |
UA113280C2 (xx) * | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
WO2012062745A1 (en) * | 2010-11-11 | 2012-05-18 | Bayer Pharma Aktiengesellschaft | Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
CN103214489B (zh) * | 2013-02-25 | 2016-10-26 | 中国人民解放军第二军医大学 | 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法 |
UA122822C2 (uk) * | 2013-04-08 | 2021-01-06 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
US10124007B2 (en) | 2013-12-03 | 2018-11-13 | Bayer Pharma Aktiengesellschaft | Combination of PI3K-inhibitors |
CA2932221C (en) | 2013-12-03 | 2022-02-22 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
WO2015082376A2 (en) | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Use of pi3k-inhibitors |
WO2016071382A1 (en) * | 2014-11-07 | 2016-05-12 | Bayer Pharma Aktiengesellschaft | Synthesis of pi3k inhibitor and salts thereof |
WO2016071380A1 (en) * | 2014-11-07 | 2016-05-12 | Bayer Pharma Aktiengesellschaft | Synthesis of pi3k inhibitor and salts thereof |
WO2016087488A1 (en) * | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives |
WO2016087490A1 (en) * | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
JP2018532810A (ja) | 2015-11-07 | 2018-11-08 | マルチビア インコーポレイテッド | がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物 |
US10925880B2 (en) | 2016-09-23 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Combination of PI3K-inhibitors |
JP2020510624A (ja) | 2016-12-12 | 2020-04-09 | マルチビア インコーポレイテッド | がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物 |
WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
WO2019002068A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST |
AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
CN108383849B (zh) * | 2018-04-26 | 2020-11-06 | 浙江大学 | 咪唑并喹唑啉衍生物及其在抗肿瘤抗炎中的应用 |
CA3132229A1 (en) * | 2019-03-07 | 2020-09-10 | BioNTech SE | Process for the preparation of a substituted imidazoquinoline |
CA3157789A1 (en) * | 2019-10-15 | 2021-04-22 | Bayer Aktiengesellschaft | 2-methyl-aza-quinazolines |
WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
WO2021260443A1 (en) | 2020-06-24 | 2021-12-30 | Bayer Aktiengesellschaft | Combinations of 2,3-dihydroimidazo[1,2-c]quinazolines |
CN115572256A (zh) * | 2021-06-21 | 2023-01-06 | 武汉睿健医药科技有限公司 | Oct4高选择性活化剂 |
CN113512040B (zh) * | 2021-08-25 | 2023-10-13 | 河南牧业经济学院 | 一种血根碱仿生化合物及其制备方法 |
TW202404968A (zh) * | 2022-04-20 | 2024-02-01 | 美商思諾維新醫藥公司 | PI3Kα抑制劑 |
WO2023230262A1 (en) * | 2022-05-26 | 2023-11-30 | Synnovation Therapeutics, Inc. | Tricyclic compounds as pi3kalpha inhibitors |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
GB9400680D0 (en) | 1994-01-14 | 1994-03-09 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5792766A (en) | 1996-03-13 | 1998-08-11 | Neurogen Corporation | Imidazo 1,5-c! quinazolines; a new class of GABA brain receptor ligands |
UA82205C2 (en) * | 2002-09-30 | 2008-03-25 | Байер Фармасьютикалз Корпорейшн | Fused azole-pyrimidine derivatives |
SI1667992T1 (sl) | 2003-09-19 | 2007-06-30 | Astrazeneca Ab | Kinazolinski derivati |
BRPI0414856A (pt) * | 2003-10-03 | 2006-11-21 | 3M Innovative Properties Co | imidazoquinolinas alcóxi-substituìdas |
WO2005080392A1 (ja) * | 2004-02-19 | 2005-09-01 | Takeda Pharmaceutical Company Limited | ピラゾロキノロン誘導体およびその用途 |
PL2066653T3 (pl) | 2006-08-03 | 2013-02-28 | Rottapharm Biotech Srl | Pochodne 6-1H-imidazo-chinazoliny i chinoliny, nowe silne środki przeciwbólowe i przeciwzapalne |
AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
GB2454549B (en) * | 2007-09-25 | 2009-09-23 | Medical & Pharm Ind Tech & Dev | Uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one for providing an anti-allergic effect and histamine H1 receptor antagonism effect |
KR20110036583A (ko) | 2008-06-20 | 2011-04-07 | 로타팜 에스.피.에이. | 6-1h-이미다조-퀴나졸린 및 퀴놀린 유도체, 신규 mao 억제제 및 이미다졸린 수용체 리간드 |
CN102076689B (zh) | 2008-06-26 | 2014-10-15 | 内尔维阿诺医学科学有限公司 | 吡唑并-喹唑啉类 |
EP2168583A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
CA2796253A1 (en) | 2010-04-16 | 2011-10-20 | Bayer Intellectual Property Gmbh | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
ES2639402T3 (es) * | 2010-11-11 | 2017-10-26 | Bayer Intellectual Property Gmbh | 2,3-dihidroimidazo[1,2-c]quinolinas sustituidas con arilaminoalcohol |
WO2012062745A1 (en) * | 2010-11-11 | 2012-05-18 | Bayer Pharma Aktiengesellschaft | Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
UA113280C2 (xx) * | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ |
-
2011
- 2011-08-11 UA UAA201307179A patent/UA113280C2/uk unknown
- 2011-11-08 PE PE2013001051A patent/PE20140411A1/es not_active Application Discontinuation
- 2011-11-08 AU AU2011328192A patent/AU2011328192B2/en not_active Ceased
- 2011-11-08 EA EA201300556A patent/EA024406B1/ru not_active IP Right Cessation
- 2011-11-08 NZ NZ610018A patent/NZ610018A/en not_active IP Right Cessation
- 2011-11-08 MY MYPI2013700753A patent/MY164730A/en unknown
- 2011-11-08 JP JP2013538163A patent/JP6196156B2/ja active Active
- 2011-11-08 MX MX2013005305A patent/MX2013005305A/es unknown
- 2011-11-08 BR BR112013011634A patent/BR112013011634A2/pt not_active IP Right Cessation
- 2011-11-08 KR KR1020137014882A patent/KR20140003436A/ko not_active Application Discontinuation
- 2011-11-08 WO PCT/EP2011/069637 patent/WO2012062748A1/en active Application Filing
- 2011-11-08 CA CA2817317A patent/CA2817317C/en active Active
- 2011-11-08 EP EP11784978.6A patent/EP2638045B1/en active Active
- 2011-11-08 AP AP2013006921A patent/AP3337A/xx active
- 2011-11-08 CN CN201180023122.7A patent/CN102906094B/zh active Active
- 2011-11-08 US US13/885,122 patent/US8895549B2/en active Active
- 2011-11-08 SG SG2013033634A patent/SG190100A1/en unknown
- 2011-11-10 UY UY0001033719A patent/UY33719A/es not_active Application Discontinuation
- 2011-11-11 AR ARP110104216A patent/AR083842A1/es unknown
- 2011-11-11 TW TW100141328A patent/TW201305170A/zh unknown
-
2013
- 2013-04-30 IL IL226066A patent/IL226066A0/en unknown
- 2013-05-09 MA MA35889A patent/MA34655B1/fr unknown
- 2013-05-10 CL CL2013001295A patent/CL2013001295A1/es unknown
- 2013-05-10 GT GT201300121A patent/GT201300121A/es unknown
- 2013-05-10 DO DO2013000105A patent/DOP2013000105A/es unknown
- 2013-05-10 CU CU2013000069A patent/CU20130069A7/es unknown
- 2013-05-10 EC ECSP13012618 patent/ECSP13012618A/es unknown
- 2013-05-10 CR CR20130213A patent/CR20130213A/es unknown
- 2013-05-10 CO CO13117697A patent/CO6761350A2/es not_active Application Discontinuation
- 2013-06-10 ZA ZA2013/04244A patent/ZA201304244B/en unknown
- 2013-07-10 HK HK13108062.1A patent/HK1180685A1/zh not_active IP Right Cessation
-
2014
- 2014-11-25 US US14/553,280 patent/US9902727B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR083842A1 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a las angiogenesis | |
BRPI0707491B8 (pt) | compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas | |
ATE540037T1 (de) | Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten | |
ES2572189T3 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis | |
EA200870423A1 (ru) | Производные триазолпиразинов, применимые в качестве противораковых агентов | |
EA201391720A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
ATE517882T1 (de) | Chinolinderivate | |
MX2012001313A (es) | Compuesto espirociclicos que contienen nitrogeno y su uso medicinal. | |
JP2015522650A5 (es) | ||
RU2008107727A (ru) | Макроциклические ингибиторы вируса гепатита с | |
DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
ECSP077424A (es) | Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3 | |
EA201071040A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40 | |
MX347423B (es) | Derivados de espiro-amina ciclica como moduladores de esfingosina 1 fosfato. | |
AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
HK1138262A1 (en) | Novel phosphodiesterase inhibitors | |
RU2009144538A (ru) | Новые циклические пептидные соединения | |
JP2016513696A5 (es) | ||
EA201170722A1 (ru) | Лактамы в качестве ингибиторов бета-секретазы | |
EA201100368A1 (ru) | Амидные соединения, полезные в терапии | |
MX2009012613A (es) | Tiazoles substituidos por heteroarilo y su uso como agentes antivirales. | |
JP2016513681A5 (es) | ||
MX2009009466A (es) | Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro. | |
MX341341B (es) | Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90). | |
CO6460737A2 (es) | N-((1r,2s,5r)-5-(tert -butilamino)-2-((s)-3-(7-tert-butilpirazolo[1.5-a][1.3.5]traizin -4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |